MX2024004355A - Tratamiento de la enfermedad renal. - Google Patents
Tratamiento de la enfermedad renal.Info
- Publication number
- MX2024004355A MX2024004355A MX2024004355A MX2024004355A MX2024004355A MX 2024004355 A MX2024004355 A MX 2024004355A MX 2024004355 A MX2024004355 A MX 2024004355A MX 2024004355 A MX2024004355 A MX 2024004355A MX 2024004355 A MX2024004355 A MX 2024004355A
- Authority
- MX
- Mexico
- Prior art keywords
- kidney disease
- treatment
- therapeutic
- kidney function
- kidney
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dermatology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163255885P | 2021-10-14 | 2021-10-14 | |
| US202263307801P | 2022-02-08 | 2022-02-08 | |
| US202263321204P | 2022-03-18 | 2022-03-18 | |
| PCT/US2022/078153 WO2023064925A1 (en) | 2021-10-14 | 2022-10-14 | Treatment of kidney disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004355A true MX2024004355A (es) | 2024-06-21 |
Family
ID=85988933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004355A MX2024004355A (es) | 2021-10-14 | 2022-10-14 | Tratamiento de la enfermedad renal. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250009803A1 (https=) |
| EP (1) | EP4415729A4 (https=) |
| JP (1) | JP2024536479A (https=) |
| KR (1) | KR20240110801A (https=) |
| AU (1) | AU2022362077A1 (https=) |
| CA (1) | CA3233866A1 (https=) |
| MX (1) | MX2024004355A (https=) |
| WO (1) | WO2023064925A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025106530A1 (en) * | 2023-11-13 | 2025-05-22 | Butler Emily | Characteristics of enriched heterogeneous renal cell populations |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020266168A1 (en) * | 2019-05-02 | 2021-12-02 | ProKidney IPCo, LLC | Treatment of kidney disease in subjects with kidney and/or urinary tract anomalies |
-
2022
- 2022-10-14 AU AU2022362077A patent/AU2022362077A1/en active Pending
- 2022-10-14 US US18/699,849 patent/US20250009803A1/en active Pending
- 2022-10-14 CA CA3233866A patent/CA3233866A1/en active Pending
- 2022-10-14 JP JP2024522027A patent/JP2024536479A/ja active Pending
- 2022-10-14 KR KR1020247015819A patent/KR20240110801A/ko active Pending
- 2022-10-14 MX MX2024004355A patent/MX2024004355A/es unknown
- 2022-10-14 WO PCT/US2022/078153 patent/WO2023064925A1/en not_active Ceased
- 2022-10-14 EP EP22882059.3A patent/EP4415729A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023064925A1 (en) | 2023-04-20 |
| US20250009803A1 (en) | 2025-01-09 |
| JP2024536479A (ja) | 2024-10-04 |
| CA3233866A1 (en) | 2023-04-20 |
| KR20240110801A (ko) | 2024-07-16 |
| EP4415729A4 (en) | 2025-08-27 |
| WO2023064925A8 (en) | 2024-04-11 |
| AU2022362077A1 (en) | 2024-05-02 |
| EP4415729A1 (en) | 2024-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022009125A5 (https=) | ||
| RU2008109238A (ru) | Способы лечения заболеваний антагонистами vegf | |
| CL2019003496A1 (es) | Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| NZ596041A (en) | Use of guanethidine for treating hypertension by local vascular delivery | |
| EP4684832A3 (en) | Potassium-binding agents for treating hypertension and hyperkalemia | |
| RU2008141076A (ru) | Применение терапевтического человеческого альбумина для изготовления лекарственного средства для лечения пациентов, страдающих когнитивными расстройствами | |
| Gil et al. | Efficacy of hemocontrol biofeedback system in intradialytic hypotension-prone hemodialysis patients | |
| Santoro et al. | Vascular access for hemodialysis | |
| Qu et al. | Priapism secondary to chronic myeloid leukemia treated by a surgical cavernosa-corpus spongiosum shunt: Case report | |
| WO2021038500A3 (en) | Esketamine for the treatment of patients with major depressive disorder, including suicidality | |
| MX2024004355A (es) | Tratamiento de la enfermedad renal. | |
| CA2574450A1 (en) | Method of treating hyperphosphataemia using lanthanum hydroxycarbonate | |
| Donati et al. | Early use of PEPA dialyzer for light chains removal and for the recovery from myeloma cast nephropathy: A case report | |
| RU2014150946A (ru) | Способ снижения веса | |
| EP4245366A3 (en) | Migalastat for treating fabry patients having renal impairment | |
| RU2483723C1 (ru) | Способ лечения эндокринной офтальмопатии | |
| JOP20200046A1 (ar) | طرق لعلاج أمراض مرتبطة بـtnf? | |
| EA201590825A1 (ru) | Способы контролирования кровяного давления и снижения диспноэ при сердечной недостаточности | |
| MX2024005374A (es) | Metodos para tratar la enfermedad de celulas falciformes con voxelotor. | |
| DE202012100195U1 (de) | Neue Verwendung einer pharmazeutischen Zusammensetzung, enthaltend Ancrod | |
| CN204275131U (zh) | 一种肢体局部给药和透析装置 | |
| CN205586290U (zh) | 一种水筋针治疗系统 | |
| CN109453191A (zh) | GSK-3β抑制剂及在糖尿病肾病干预新靶点的应用 | |
| EA202192612A1 (ru) | Канаглифлозин для лечения больных диабетом пациентов с хроническим заболеванием почек | |
| WO2007011960A3 (en) | Methods and agents to treat autoimmune diseases |